Legal status of psilocybin mushrooms

Pharmadrug's Supersmart Launches Psilocybin Online Retail Platform in the Netherlands

Retrieved on: 
Monday, June 7, 2021
Fungi, Psychoactive drugs, Psychoactive fungi, Entheogens, Psilocybin, Shrooms, Truffle, Magic truffle, Legal status of psilocybin mushrooms

The European Slim Winkel online store will sell psilocybin truffles as well as functional mushrooms in The Netherlands.

Key Points: 
  • The European Slim Winkel online store will sell psilocybin truffles as well as functional mushrooms in The Netherlands.
  • The website will also service other parts of Europe, but without the access to psilocybin truffles.
  • Secondly, it will enable the company to continue to curate quality products, which will eventually include its own branded psilocybin truffles in The Netherlands.
  • Thirdly, it will enable Super Smart to continue to develop its psilocybin supply chain.

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

Retrieved on: 
Tuesday, May 25, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Psilocybin, Legal status of psilocybin mushrooms

Under the new guidance from Health Canada, Mydecine will begin construction of expanded cultivation facilities in an effort to scale its supply of pharmaceutical grade psilocybin for both internal clinical research and its industry partners.

Key Points: 
  • Under the new guidance from Health Canada, Mydecine will begin construction of expanded cultivation facilities in an effort to scale its supply of pharmaceutical grade psilocybin for both internal clinical research and its industry partners.
  • The increased cultivation will also allow the Company to more efficiently and quickly study the medical utility of naturally occurring psilocybin and psilocybin-like compounds.
  • Nature has produced a diversity of psilocybin producing fungi, all with their own unique chemistry and much of this diversity remains unstudied or undiscovered.
  • The expansion of our cultivation capabilities will give us a unique lens into better understanding this incredible diversity and how it may be utilized in a therapeutic setting.

Psirenity signs partnership with Jamaica’s Scientific Research Council to conduct joint studies into beneficial effects of psilocybin mushrooms

Retrieved on: 
Thursday, April 1, 2021
Entheogens, Psychoactive drugs, Psychoactive fungi, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Legal status of psilocybin mushrooms

TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaicas Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.

Key Points: 
  • TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaicas Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.
  • Under the new partnership, SRC, Jamaicas principal public sector agency responsible for scientific research and development, will provide technical support, technology transfer and physical and human resources that will allow Psirenity to develop imaginative new mental health treatments.
  • This new collaboration will help Psirenity streamline and scale-up production of psilocybin mushrooms to develop critical nutraceutical and pharmaceutical products, McCullough said.
  • Psirenity believes creating advanced psilocybin therapies for mental health and offering proprietary psycho-educational programs, as well as evidence-based therapeutics and nutraceuticals, can help advance human achievement through enhanced psychedelics.

OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development

Retrieved on: 
Tuesday, March 2, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Psilocybin, Psilocybe, Psilocin, Psychedelic drug, Legal status of psilocybin mushrooms, Psilocybe cubensis

Optimi applied for and has received a research exemption from Health Canada allowing it to conduct research activities involving psychedelic compounds, specifically psilocybin and psilocin.

Key Points: 
  • Optimi applied for and has received a research exemption from Health Canada allowing it to conduct research activities involving psychedelic compounds, specifically psilocybin and psilocin.
  • Optimi has further applied for and is awaiting approval of a dealers license necessary to undertake certain additional aspects of its research and development.
  • The Company has elected to move ahead by undertaking several research and development projects with Numinus specifically related to Psilocybe mushrooms, psychedelic compounds, and formulations within their licensed facilities.
  • Numinus Wellness Inc. is a health care and research company creating psychedelic-centered solutions to treat mental illness, substance abuse and trauma.

Medical Breakthroughs Propel Psilocybin Closer to Legalization

Retrieved on: 
Monday, March 1, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Branches of biology, Psilocybin mushroom, Psilocybin, Mushroom, Psychedelic drug, Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States

For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).

Key Points: 
  • For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Mindleap's software patents will strengthen our intellectual property portfolio overall which now totals 8 patent filings currently in process.'
  • The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs.

Medical Breakthroughs Propel Psilocybin Closer to Legalization

Retrieved on: 
Monday, March 1, 2021
Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Branches of biology, Psilocybin mushroom, Psilocybin, Mushroom, Psychedelic drug, Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States

For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).

Key Points: 
  • For example, earlier in 2019, Colorado became the first state to decriminalize magic mushrooms (mushrooms containing psilocybin).
  • Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
  • 'Mindleap's software patents will strengthen our intellectual property portfolio overall which now totals 8 patent filings currently in process.'
  • The Mindleap platform brings convenience, improves access to treatments and can lead to more personal breakthroughs.

ATMA Launches Canada's First Psychedelic Training Program for Mental Health Professionals that Includes a Legal Psychedelic Experience

Retrieved on: 
Friday, February 12, 2021
Psychoactive drugs, Entheogens, Branches of biology, Psychiatry, Psychoactive fungi, Drug discovery, Psychedelic therapy, Psychedelic drug, Psilocybin mushroom, Psilocybin, Mental health, Legal status of psilocybin mushrooms

Starting in March 2021, ATMA and Wayfoundwill present the Psychedelic Therapy Training Program for Mental Health Professionals, which will take place through remote training as well as on-site at ATMA's Calgary Journey Center.

Key Points: 
  • Starting in March 2021, ATMA and Wayfoundwill present the Psychedelic Therapy Training Program for Mental Health Professionals, which will take place through remote training as well as on-site at ATMA's Calgary Journey Center.
  • The training allows participants to apply for an exemption from Health Canada to experience legal psychedelic-assisted therapy using psilocybin, one of the active compounds found in 'magic mushrooms'.
  • Incorporating hands-on experience with psychedelics for therapists in a legal setting is a first for the mental health community in Canada.
  • Each participant of the professional training program will also be assisted in obtaining their own exemption from Health Canada so that they may personally undergo psychedelic-assisted therapy.

Allied Moves to Become Leader in Psilocybin Space with Intent to Acquire of Pacific Sun Fungi

Retrieved on: 
Thursday, December 24, 2020
Entheogens, Psychoactive fungi, Psychoactive drugs, Articles, Branches of biology, Abnormal psychology, Aftermath of war, Post-traumatic stress disorder, Psilocybin, Legal status of psilocybin mushrooms

Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years.

Key Points: 
  • Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years.
  • Over the past two years, in parallel with psilocybin moving into the pharmaceutical research realm, Allied has continued to develop its pharmaceutical research infrastructure.
  • Allied was born out of the need to support veterans and first responders suffering from PTSD with targeted cannabinoid solutions.
  • On December 20th, 2020, Allied moves to acquire Pacific Sun Fungi by signing Letter of Intent to acquire.

Way2Grow (W2G) Biopharma Company Enters Cannabis Productivity and Announces Plans to Seek Health Canada Approval for Magic Mushroom (Psilocybin and Psilocin) Dealer and Research Licencing

Retrieved on: 
Tuesday, December 15, 2020
Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Organisms, Psilocybin mushroom, Psilocybin, Cannabis, Medical cannabis, Psilocybe semilanceata, Psilocybe, Legal status of psilocybin mushrooms

Way2Grow received approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements.

Key Points: 
  • Way2Grow received approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements.
  • W2Gs research plans include the investigation of cannabis and psilocybin mushrooms growth plans and examination of their efficacy on treating unmet mental health conditions such as PTSD, addiction dependency, and anxiety.
  • W2Gs cultivation relies on a small, closed room approach to growing consistent organic medical cannabis and soon, medical grade psilocybin mushroom (Psilocybe semilanceata) production.
  • Way2Grow is located in Osoyoos, British Columbia, and is regulated under the Cannabis Act and the Cannabis Regulations (Canada).

New Wave Holdings Congratulates TheraPsil's Advocacy to Bring Psilocybin Therapy to Palliative Care for Canadian Patients

Retrieved on: 
Thursday, December 10, 2020
Psychoactive drugs, Health sciences, Entheogens, Psilocybe, Psilocybin therapy, Drug discovery, Psychoactive fungi, Psilocybin, Therapy, Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States

17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy.

Key Points: 
  • 17 healthcare professionals associated with TheraPsil, a non-profit, patient-rights advocacy group, have been approved by the Federal Health Minister, Patty Hajdu, to possess and use psilocybin for professional training in psilocybin therapy.
  • New Wave is proud to have sponsored TheraPsil in this journey and applaud the hard work conducted by the team and all the various partners involved.
  • TheraPsil is a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for Canadians in medical need.
  • TheraPsil, supports patients with their applications for ministerial approval of psilocybin for medical purposes and connects approved patients with qualified practitioners to receive psilocybin-assisted therapy treatment.